- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
UroGen Gets $7.5 Million Payment from Licensing Agreement
Thanks to an IND application for RTGel from Allergan, UroGen Pharma will receive a $7.5 million licensing agreement payment.
Thanks to an Investigational New Drug (IND) application for RTGel from Allergan, UroGen Pharma (NASDAQ:URGN) will receive a $7.5 million licensing agreement payment.
As quoted in the press release:
“Our licensing agreement with Allergan for the use of our RTGel in combination with BOTOX® continues to be productive with the recent achievement of this important IND submission,” said Ron Bentsur, Chief Executive Officer of UroGen. “We are excited about the potential of the RTGel/BOTOX® combination to become an important additional treatment option for patients suffering from overactive bladder.”
In October 2016, UroGen granted an exclusive worldwide license to Allergan to develop and commercialize pharmaceutical products that contain UroGen’s proprietary RTGel and clostridial toxins, including BOTOX®. UroGen is eligible to receive additional payments related to the achievement of certain development, regulatory, and commercial milestones, in addition to royalties on potential net sales.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.